Abstract:Objective To study the therapeutic effects and side effect of nuclide 131 I or 125 I,anti AFP antibody(AFP Ab),MMC and 125 I lipiodol ultra fluide(LUF)used as targeting therapy for primary liver cancer (PLC). Methods AFP Ab was used as targeting carrier, and the nuclide 131 I and 125 I and the anticancer drug MMC as the warheads. The PLC patients were divided into:Group A, 72 cases received 131 I AFP Ab;Group B, 22 cases received 125 I AFP Ab:Group C, 21 cases received AFP Ab MMC;Group D, 41 cases, received 131 I (or 125 I )AFP Ab MMC;and Group E, 38 cases received 125 I LUF.Results 1 A clear image of tumor were shown in SPECT scanning.After injection of drugs, the tumor/liver (T/L) radioactivity ratio in Group E was 3.46,in Group D 2.66 , and in Group B 1.86. 2 The 1 year survival rate in Group E was 81.6%, the highest, followed by Group D 58.5%,Group B 47.1%,Group A 33.3%, and Group C 19.0%. 3 In Group E, 18 cases received additional external radiation and the 1 year rate reached 100%. 4. After targeting therapy, the tumors of 9 cases withered enough and were resected, 8 of them survived for 3 years (88.9%). Conclusion 1 This kind of targeting therapy is effective in killing massive liver cancer cells. 2 The efficacy is concerned with the synergy of antibody, nuclide in ternal radiation and anticancer drug. 3. The internal radiation of 125 I LUF plus external radiation may give some improving effect for late liver cancer cases.

Clinical study on targeting therapy of liver cancer(Clinical Study from 1980 to 1999)